-
Phase III Data in July = Next Dendreon !!!
Urocidin (Bladder Cancer) Phase III Results within 4 Weeks .Lots will want this goldmine in the future. Please do your own Homework .
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!!
Market Cap: 75 Mio $
Cash: 22 Mio $
Price: 1,03 $
Buy rating by Dundee Sec (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle *****, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals (ENDP 22.13 ?1.10%) (NASDAQ:ENDP). Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says.
-
-
News ...Up to 1$ in Pre-Market !
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform
Press Release Source: Bioniche Life Sciences Inc. On Wednesday June 23, 2010, 7:00 am EDT
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform - Yahoo! Finance
-
GOOD PHASE III RESULTS IS COMING VERY SOON !!
BNC IS READY TO TAKEOFF
Investors Hub - Charts
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
-
Must be out soon either Phase3 news or Econiche approval news are about to hit the wire.I'm feeling very optimistic . Let's get rolling.
Buy signal is created
BNC.TO | Stock Price Quote for Bioniche Life Scie Com Npv
BNC.TO | Stock Trader's Cheat Sheet for Bioniche Life Scie Com Npv
Best-Rated Canadian Stocks Updated Jul 11, 2010 - NASD100.com - Daily Stock Rankings
Best-Rated Canadian Stocks Updated Jul 11, 2010
TOP 10 Lists; Up on Unusual Volume;Down on Unusual Volume;52-Week Highs; 52-Week Lows
Below are the best-rated Canadian stocksbased on average Wall Street analyst ratings.Each analyst rating is assigned a number ranging from 1 to5, with 1 being the highest rating (STRONG BUY) and 5 being thelowest rating (STRONG SELL). Then the average is calculated torepresent the overall rating of a stock.
Ranking | Company (Ticker) | Average Rating Value |Average Rating
1 Alarm Force Industries (TSE:AF) 1.00 StrongBuy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 AmorfixLife Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 StrongBuy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy <<<<<< STRONG BUY <<<<<<<
-
Looks good today ..I smell good news ! Glta
-
Some Positive Signs ..
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma | Reuters
---
Bioniche obtains two additional milestones under licensing agreement with Endo
Online Stock Trading Investing Day Trading | TradingMarkets.com
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--
All DMC (Data Monitoring Committee) are Positive !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
-
Junior Member
- Rep Power
- 0
Bioniche Life Science (BNC.TO) ISIN CODE please ?
-
ISIN: CA09063P1099
Bioniche is moving higher ....
Investors Hub - Charts
-
Bioniche is on the move ..last chance to get in cheap ! glta
Investors Hub - Charts
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules
LinkBack URL
About LinkBacks
Reply With Quote